Cencora, Inc. $COR Shares Sold by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC reduced its holdings in Cencora, Inc. (NYSE:COR) by 4.6% in the 4th quarter, HoldingsChannel reports. The fund owned 423,026 shares of the company’s stock after selling 20,575 shares during the period. Cencora comprises approximately 2.2% of TimesSquare Capital Management LLC’s holdings, making the stock its 3rd biggest position. TimesSquare Capital Management LLC’s holdings in Cencora were worth $142,877,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its position in Cencora by 13.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock valued at $15,086,000 after acquiring an additional 5,543 shares during the period. AustralianSuper Pty Ltd acquired a new position in Cencora in the 3rd quarter valued at approximately $26,191,000. Mediolanum International Funds Ltd increased its position in Cencora by 133.0% in the 3rd quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock valued at $17,342,000 after acquiring an additional 32,138 shares during the period. Chilton Investment Co. Inc. acquired a new stake in shares of Cencora during the third quarter worth $459,000. Finally, Advisors Asset Management Inc. increased its position in shares of Cencora by 40.3% during the third quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock worth $5,407,000 after buying an additional 4,973 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Up 1.7%

Shares of NYSE COR opened at $262.15 on Tuesday. The firm has a market cap of $51.00 billion, a PE ratio of 20.10, a P/E/G ratio of 1.19 and a beta of 0.64. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The company’s fifty day simple moving average is $312.71 and its 200 day simple moving average is $338.72. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm’s revenue was up 3.9% compared to the same quarter last year. During the same period in the prior year, the company earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts forecast that Cencora, Inc. will post 17.76 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, May 15th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s payout ratio is presently 18.40%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Wells Fargo & Company decreased their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Morgan Stanley set a $342.00 price objective on shares of Cencora in a research report on Friday, May 8th. Robert W. Baird decreased their price objective on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Twelve analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.